Email this article Opyt uspeshnogo lecheniya HER2-pozitivnogo metastaticheskogo raka zheludka
- Authors: Gamayunov SV1, Slugarev VV1, Ter-Ovanesov MD1, Zakharova EM1
-
Affiliations:
- Issue: Vol 14, No 2 (2012)
- Pages: 41-45
- Section: Articles
- Submitted: 09.04.2020
- Published: 15.06.2012
- URL: https://modernonco.orscience.ru/1815-1434/article/view/29499
- ID: 29499
Cite item
Full Text
Abstract
References
- Incidence, mortality and prevalence Worldwide in 2008. Global cancer statistic, IARC. http://globocan.iarc.fr/factsheet.asp
- Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Вестник РОНЦ им. Н.Н.Блохина РАМН (Прил. 1). 2011; 22 (3): 85.
- Best practice in Gastric cancer and adenocarcinoma of the Esophagogastric Junction. Ed. Salah-Eddin Al-Batran. 1st ed. GmbH 2011.
- Petrelli NJ et al. Успехи клинической онкологии 2009: наиболее значимые достижения в лечении, профилактике и скрининге онкологических заболеваний. Сообщение Американского общества клинической онкологии (ASCO). JCO 2010; 4 (1): 76-94.
- Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007; 357 (1): 39-51.
- Barros-Silva JD, Leitão D, Afonso L et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009; 100: 487-93. http:// www.bjcancer.com
- Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376 (9742): 687-97.
- Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathol 2008; 52 (7): 797-805.
- Rüschoff J et al. Der Pathologe 2010; 31: 208-17.
Supplementary files
